Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Ruxolitinib | 0.3 | uM | 1 | RANTES | 69.5 | 66 | ||||
N2586 | Tofacitinib | 0.3 | uM | 1 | RANTES | 131.0 | 53 | ||||
N2586 | IKK16 | 2.0 | uM | 1 | RANTES | 88.5 | 50 | ||||
N2586 | JNK-IN-8 | 3.0 | uM | 1 | RANTES | 72.0 | 64 | ||||
RA2159 | EGF | 100 | ng/mL | 1 | RANTES | 257.0 | 63 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 1 | RANTES | 141.0 | 51 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | RANTES | 109.0 | 53 | |
RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | RANTES | 92.0 | 67 | |
RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | RANTES | 175.0 | 70 | |
RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 1 | RANTES | 92.0 | 55 | |
RA2159 | JNK-IN-11 | 0.3 | uM | 1 | RANTES | 155.0 | 62 | ||||
N2586 | EGF | 100 | ng/mL | 1 | RANTES | 78.0 | 68 | ||||
N2586 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 1 | RANTES | 115.0 | 64 | |
N2586 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | RANTES | 50.0 | 55 | |
N2586 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | RANTES | 104.0 | 35 | |
N2586 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | RANTES | 97.5 | 74 | |
N2586 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 1 | RANTES | 259.0 | 46 | |
N2586 | JNK-IN-11 | 0.3 | uM | 1 | RANTES | 206.0 | 52 | ||||
RA2159 | IGF-I | 100 | ug/mL | 1 | RANTES | 145.5 | 54 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 1 | RANTES | 98.0 | 54 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 1 | RANTES | 101.5 | 62 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 1 | RANTES | 96.0 | 50 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 1 | RANTES | 127.5 | 88 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 1 | RANTES | 151.5 | 74 | |
RA2159 | 1 | RANTES | 97.0 | 73 |